Analysis of Clinical Characteristics and Treatment Trends in Hospitalized Patients with Cardiovascular Diseases in the Baise ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-'408TEV-' ...
The growth of the Refurbished Medical Imaging Equipment Market is driven by cost-effectiveness, increasing demand in emerging economies, and the growing need to reduce healthcare expenses. However, ...
This study quantitatively investigates the relationship between the implementation of waste-to-resource systems and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results